Recruiting

Observational Study

Sponsor:

Abramson Cancer Center at Penn Medicine

Code:

NCT04452162

Conditions

Salivary Gland Tumor

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MRI

Study Details

Brief summary:

The goal of this study is to use advanced Magnetic Resonance Imaging (MRI) techniques to help identify the difference between cancerous and non-cancerous salivary gland tumors for improving treatment strategies and to aid in the prediction of disease progression.

Conditions

Salivary Gland Tumor

Study ID

NCT04452162

Start date

Aug 25, 2020

Status verified date

Sep, 2025

Completion date

Jun, 2026

Anticipated

Primary completion date

Jun, 2026

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Possess a salivary gland lesion of 1cm3 size
  • Have no prior history of treatment for salivary gland lesion

Exclusion Criteria:

  • Has any prior history of cancer other than SGT
  • Has any MRI contra-indications
  • Has a history of known renal disease.
  • Has history of prior radiation to head and neck region
  • Is pregnant

Study Design

Enrollment

30 participants

Anticipated

Intervention Model

Single group

Primary purpose

Diagnostic

Interventions and Outcome Measures

Arms

other: Salivary Gland Tumor

Interventions

MRI

You are being asked to complete one research MRI scan with and without contrast since your most recent clinical evaluation and/or prior imaging has shown the presence of a suspicious salivary gland tumor, prior to your scheduled upcoming surgery. MRI contrast agents act like a dye to make MRI pictures brighter and easier to read. During each MRI scan, you will have an intravenous line (IV line) placed. The IV line allows the contrast agent to be injected into your vein. If you have a history of renal disease you may be asked to complete a blood draw of approximately 2.5cc (½ teaspoon), for glomerular filtration rate (GFR) assessment for participation into the study.

Primary outcome measure

  • Differentiation and Progression Free [ Time Frame: 6 Month after the end of treatment ]

Central Contacts and Locations

Central contacts

Marisa Sanchez

2159019994Marisa.Sanchez@pennmedicine.upenn.edu

Lisa Desiderio

610-721-3365lisa.desiderio@pennmedicine.upenn.edu

Locations

Hospital of the University of Pennsylvania

Recruiting

Philadelphia, Pennsylvania, United States, 19104

Contacts

Marisa Sanchez

Marisa.Sanchez@pennmedicine.upenn.edu

Leeanne Lezotte

856-364-3137leeanne.lezotte@pennmedicine.upenn.edu

Principal Investigator:

Sanjeev Chawla

More Information

Sponsor

Abramson Cancer Center at Penn Medicine

Last update posted

Sep 9, 2025

Last verified

Sep, 2025

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-08. This information was provided to ClinicalTrials.gov by Abramson Cancer Center at Penn Medicine on 2025-09-09.